相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
Sofie Wilgenhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A cell-based microarray to investigate combinatorial effects of microparticle-encapsulated adjuvants on dendritic cell activation
Abhinav P. Acharya et al.
JOURNAL OF MATERIALS CHEMISTRY B (2016)
PD-1 marks dysfunctional regulatory T cells in malignant gliomas
Daniel E. Lowther et al.
JCI INSIGHT (2016)
Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression
David Anz et al.
CANCER RESEARCH (2015)
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Elizabeth Buchbinder et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Evan J. Lipson et al.
SEMINARS IN ONCOLOGY (2015)
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity
Kevin Van der Jeught et al.
Oncotarget (2015)
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula
Sandra Van Lint et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Pancreatic Cancer-Specific Cell Death Induced In Vivo by Cytoplasmic-Delivered Polyinosine-Polycytidylic Acid
Praveen Bhoopathi et al.
CANCER RESEARCH (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes
Menna R. Clatworthy et al.
NATURE MEDICINE (2014)
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
Hatem H. Soliman et al.
ONCOTARGET (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
Claudia Duran-Aniotz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Localized Immunotherapy via Liposome-Anchored Anti-CD137+IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
Brandon Kwong et al.
CANCER RESEARCH (2013)
A high-throughput nanoimmunoassay chip applied to large-scale vaccine adjuvant screening
Jose L. Garcia-Cordero et al.
INTEGRATIVE BIOLOGY (2013)
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Aurelien Marabelle et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
Stephen R. Goding et al.
JOURNAL OF IMMUNOLOGY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effects of Microparticle Size and Fc Density on Macrophage Phagocytosis
Patricia Pacheco et al.
PLOS ONE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
The RIG-I-like Receptor LGP2 Controls CD8+ T Cell Survival and Fitness
Mehul S. Suthar et al.
IMMUNITY (2012)
TRAIL+ Human Plasmacytoid Dendritic Cells Kill Tumor Cells In Vitro: Mechanisms of Imiquimod- and IFN-α-Mediated Antitumor Reactivity
Madeleine L. Kalb et al.
JOURNAL OF IMMUNOLOGY (2012)
RLR-mediated production of interferon-β by a human dendritic cell subset and its role in virus-specific immunity
Attila Szabo et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
A functionalizable reverse thermal gel based on a polyurethane/PEG block copolymer
Daewon Park et al.
BIOMATERIALS (2011)
Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors
Fernando Aranda et al.
CANCER RESEARCH (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Intravital microscopy imaging of macrophage localization to immunogenic particles and co-localized tissue oxygen saturation
Se-woon Choe et al.
ACTA BIOMATERIALIA (2010)
Targeted Activation of RNA Helicase Retinoic Acid-Inducible Gene-I Induces Proimmunogenic Apoptosis of Human Ovarian Cancer Cells
Kirsten Kuebler et al.
CANCER RESEARCH (2010)
Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma
Shari Pilon-Thomas et al.
JOURNAL OF IMMUNOLOGY (2010)
TLR3 and Rig-Like Receptor on Myeloid Dendritic Cells and Rig-Like Receptor on Human NK Cells Are Both Mandatory for Production of IFN-γ in Response to Double-Stranded RNA
Ivan Perrot et al.
JOURNAL OF IMMUNOLOGY (2010)
Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
Sara M. Mangsbo et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Rationalizing the development of live attenuated virus vaccines
Adam S. Lauring et al.
NATURE BIOTECHNOLOGY (2010)
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
Nam Trung Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Regulation of Adaptive Immunity by the Innate Immune System
Akiko Iwasaki et al.
SCIENCE (2010)
Indoleamine 2,3-Dioxygenase Is Involved in Defense against Neospora caninum in Human and Bovine Cells
Katrin Spekker et al.
INFECTION AND IMMUNITY (2009)
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Stefan Loeb et al.
NATURE REVIEWS CANCER (2009)
Adhesive substrate-modulation of adaptive immune responses
Abhinav P. Acharya et al.
BIOMATERIALS (2008)
Tumor-specific Th17-polarized cells eradicate large established melanoma
Pawel Muranski et al.
BLOOD (2008)
Role of particle size in phagocytosis of polymeric microspheres
Julie A. Champion et al.
PHARMACEUTICAL RESEARCH (2008)
DNA vaccines: precision tools for activating effective immunity against cancer
Jason Rice et al.
NATURE REVIEWS CANCER (2008)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines
RJ Cox et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2004)
Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody
AP Vicari et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Pre-existing immunity to tyrosinase-related protein (TRIP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy
HT Khong et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
